→ Frank Mathias is calling it quits as CEO of German CDMO Rentschler Biopharma, moving instead to UK gene and cell therapy player Oxford Biomedica in March 2023. At that time, he’ll also return to the familiar confines of the Rentschler supervisory board, which he first joined in 2013 before vaulting to CEO three years later. Oxford Biomedica’s longtime CEO John Dawson retired in January, and interim chief Roch Doliveux will get to focus solely on his role as chairman once Mathias arrives.
As Rentschler initiates the search for Mathias’ replacement, there’s been no shortage of new appointments here in the last year — and Christiane Bardroff was just promoted to COO last week.
→ Teva is well ahead of schedule with its CEO transition, getting a…
Click here to view original post